Changes to Health Canada Medical Device Applications 

Health Canada has issued several guidance documents that take effect in early 2026 and will directly impact how medical device applications must be prepared and submitted. The most significant update is the new Guidance on managing applications for medical device licence, which was published 21 November 2025 and came into force 2 February 2026. 

Along with this guidance, Health Canada has implemented major changes to medical device application submissions as of January 2026. Mandatory use of the Regulatory Enrolment Process (REP) via the Common Electronic Submission Gateway (CESG) is now required for Class II, III, and IV device submissions, replacing email submissions. This includes new and amendment MDL applications, and all other application-related regulatory transactions. 

Key Changes Effective as of this Year: 

• Management Application Guidance: An updated Guidance on Managing Applications for Medical Device Licences (version 5) published on November 11, 2025, took effect on February 2, 2026. This guidance replaces the 2020 version and introduces stricter timelines and new screening procedures for deficiencies. It applies to all in-progress, new, and reconsideration requests. 

• Mandatory Regulatory Enrolment Process (REP): Effective January 2026, all medical device submissions and amendments for Class II, III, and IV devices must be filed using the web-based Regulatory Enrolment Process (REP), see Guidance document: regulatory enrolment process (REP) for medical devices. 

• Mandatory Use of CESG: Effective January 2026, in parallel with the implementation of the REP, all applications must now be submitted through the Common Electronic Submissions Gateway (CESG). Submissions via email are no longer accepted. 

• Terms and Conditions (T&Cs) Framework: New guidance for applying and managing Terms and Conditions on Class II-IV device licenses became effective on January 1, 2026, allowing Health Canada more post-market oversight. It is intended to enhance Health Canada’s ability to monitor medical devices throughout their lifecycle by imposing legally binding obligations on license holders. Read the full guidance at Guidance on terms and conditions for class II to IV medical devices – Canada.ca. 

These updates are designed to streamline the process, requiring digital, structured data rather than email submissions. Failure to use the REP system may result in application delays. 

Further to the above updates, be advised that Health Canada has officially adopted the International Medical Device Regulators Forum (IMDRF) table of contents format for submissions to align with global standards. This guidance was published on November 11, 2025, Guidance Document on IMDRF Table of Contents for Medical Device Applications. 

How MedEnvoy Can Support 

MedEnvoy provides strategic regulatory and market access support to medical device and IVD manufacturers seeking to enter and grow in regulated markets worldwide. We guide companies through the full product lifecycle, from regulatory planning and pre-market submissions to post-market compliance and ongoing regulatory maintenance. 

Our team stays current with evolving regulatory requirements to help ensure submissions are aligned with the latest guidance. In addition to this support, we assist with broader regulatory strategy, compliance oversight, and In-Country Representation where required. If you have any questions regarding this summary or the accompanying guidance document, we encourage you to reach out to our regulatory experts, here.